These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 28516890)

  • 101. Shorter disease duration is important for tocilizumab to achieve Boolean remission.
    Kawasaki Y; Hashimoto T; Okano T; Sakai Y; Yamane T; Shiozawa K; Shiozawa S; Hashiramoto A
    Mod Rheumatol; 2013 Nov; 23(6):1192-7. PubMed ID: 23380997
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis.
    Maldonado-Montoro M; Cañadas-Garre M; González-Utrilla A; Plaza-Plaza JC; Calleja-Hernández MŸ
    Pharmacol Res; 2016 Sep; 111():264-271. PubMed ID: 27339827
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis.
    Reiss WG; Devenport JN; Low JM; Wu G; Sasso EH
    Rheumatol Int; 2016 Feb; 36(2):295-300. PubMed ID: 26026604
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study.
    Nishimoto N; Amano K; Hirabayashi Y; Horiuchi T; Ishii T; Iwahashi M; Iwamoto M; Kohsaka H; Kondo M; Matsubara T; Mimura T; Miyahara H; Ohta S; Saeki Y; Saito K; Sano H; Takasugi K; Takeuchi T; Tohma S; Tsuru T; Ueki Y; Yamana J; Hashimoto J; Matsutani T; Murakami M; Takagi N
    Mod Rheumatol; 2014 Jan; 24(1):17-25. PubMed ID: 24261754
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study.
    Nakamura S; Suzuki K; Iijima H; Hata Y; Lim CR; Ishizawa Y; Kameda H; Amano K; Matsubara K; Matoba R; Takeuchi T
    Arthritis Res Ther; 2016 Jul; 18():159. PubMed ID: 27435242
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis.
    Hoffman E; Rahat MA; Feld J; Elias M; Rosner I; Kaly L; Lavie I; Gazitt T; Zisman D
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540528
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients-A longitudinal analysis.
    Wunderlich C; Oliviera I; Figueiredo CP; Rech J; Schett G
    Semin Arthritis Rheum; 2017 Jun; 46(6):709-714. PubMed ID: 28109618
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis.
    Pers YM; Schaub R; Constant E; Lambert J; Godfrin-Valnet M; Fortunet C; Bourichi W; Prades BP; Wendling D; Gaudin P; Jorgensen C; Maillefert JF; Marotte H
    Joint Bone Spine; 2015 Jan; 82(1):25-30. PubMed ID: 25241333
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Subcutaneous tocilizumab: recent advances for the treatment of rheumatoid arthritis.
    Ogata A; Kato Y; Higa S; Maeda K
    Expert Opin Drug Deliv; 2019 Jun; 16(6):639-648. PubMed ID: 31088167
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials.
    Moots RJ; Sebba A; Rigby W; Ostor A; Porter-Brown B; Donaldson F; Dimonaco S; Rubbert-Roth A; van Vollenhoven R; Genovese MC
    Rheumatology (Oxford); 2017 Apr; 56(4):541-549. PubMed ID: 28013198
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Serum GM-CSF level is a predictor of treatment response to tocilizumab in rheumatoid arthritis patients: a prospective observational cohort study.
    Su J; Hu W; Ding Y; Zhang P; Li T; Liu S; Xing L
    Arthritis Res Ther; 2024 Jul; 26(1):130. PubMed ID: 38997725
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Tocilizumab modulates serum levels of adiponectin and chemerin in patients with rheumatoid arthritis: potential cardiovascular protective role of IL-6 inhibition.
    Fioravanti A; Tenti S; Bacarelli MR; Damiani A; Li Gobbi F; Bandinelli F; Cheleschi S; Galeazzi M; Benucci M
    Clin Exp Rheumatol; 2019; 37(2):293-300. PubMed ID: 30148441
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Clinical and structural remission rates increased annually and radiographic progression was continuously inhibited during a 3-year administration of tocilizumab in patients with rheumatoid arthritis: A multi-center, prospective cohort study by the Michinoku Tocilizumab Study Group.
    Hirabayashi Y; Munakata Y; Miyata M; Urata Y; Saito K; Okuno H; Yoshida M; Kodera T; Watanabe R; Miyamoto S; Ishii T; Nakazawa S; Takemori H; Ando T; Kanno T; Komagamine M; Kato I; Takahashi Y; Komatsuda A; Endo K; Murai C; Takakubo Y; Miura T; Sato Y; Ichikawa K; Konta T; Chiba N; Muryoi T; Kobayashi H; Fujii H; Sekiguchi Y; Hatakeyama A; Ogura K; Sakuraba H; Asano T; Kanazawa H; Suzuki E; Takasaki S; Asakura K; Sugisaki K; Suzuki Y; Takagi M; Nakayama T; Watanabe H; Miura K; Mori Y;
    Mod Rheumatol; 2016 Nov; 26(6):828-835. PubMed ID: 26934116
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums.
    Navarro G; Taroumian S; Barroso N; Duan L; Furst D
    Semin Arthritis Rheum; 2014 Feb; 43(4):458-69. PubMed ID: 24262929
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Differential effects of IL-6 blockade tocilizumab and TNF inhibitors on angiogenesis in synovial tissues from patients with rheumatoid arthritis.
    Hirohata S; Abe A; Murasawa A; Kanamono T; Tomita T; Yoshikawa H
    Mod Rheumatol; 2017 Sep; 27(5):766-772. PubMed ID: 27846751
    [TBL] [Abstract][Full Text] [Related]  

  • 116. IL-6 receptor inhibition modulates type III collagen and C-reactive protein degradation in rheumatoid arthritis patients with an inadequate response to anti-tumour necrosis factor therapy: analysis of connective tissue turnover in the tocilizumab RADIATE study.
    Juhl P; Thudium CS; Gudmann NS; Karsdal MA; Bay-Jensen AC; Siebuhr AS
    Clin Exp Rheumatol; 2018; 36(4):568-574. PubMed ID: 29465346
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Interleukin-6 (IL-6) Receptor Antagonist Protects Against Rheumatoid Arthritis.
    Li S; Wu Z; Li L; Liu X
    Med Sci Monit; 2016 Jun; 22():2113-8. PubMed ID: 27322646
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study.
    Gabay C; Riek M; Hetland ML; Hauge EM; Pavelka K; Tomšič M; Canhao H; Chatzidionysiou K; Lukina G; Nordström DC; Lie E; Ancuta I; Hernández MV; van Riel PL; van Vollenhoven R; Kvien TK
    Ann Rheum Dis; 2016 Jul; 75(7):1336-42. PubMed ID: 26374404
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Analysis of effectiveness, safety and optimization of tocilizumab in a cohort of patients with rheumatoid arthritis in clinical practice.
    Mena-Vázquez N; Manrique-Arija S; Rojas-Giménez M; Ureña-Garnica I; Jiménez-Núñez FG; Fernández-Nebro A
    Reumatol Clin (Engl Ed); 2019; 15(1):21-26. PubMed ID: 28676287
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis.
    Kawashiri SY; Kawakami A; Yamasaki S; Imazato T; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Nakamura H; Ida H; Origuchi T; Ueki Y; Eguchi K
    Rheumatol Int; 2011 Apr; 31(4):451-6. PubMed ID: 20024554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.